Anticancer Effect of COX-2 Inhibitor DuP-697 Alone and in Combination with Tyrosine Kinase Inhibitor (E7080) on Colon Cancer Cell Lines

  • Altun, Ahmet (Department of Pharmacology, Faculty of Medicine, Cumhuriyet University) ;
  • Turgut, Nergiz Hacer (Department of Pharmacology, Faculty of Medicine, Cumhuriyet University) ;
  • Kaya, Tijen Temiz (Department of Pharmacology, Faculty of Medicine, Cumhuriyet University)
  • Published : 2014.04.01


Colorectal cancer remains one of the most common types of cancer and a leading cause of cancer death worldwide. In this study, we aimed to investigate effects of DuP-697, an irreversible selective inhibitor of COX-2 on colorectal cancer cells alone and in combination with a promising new multi-targeted kinase inhibitor E7080. The HT29 colorectal cancer cell line was used. Real time cell analysis (xCELLigence system) was conducted to determine effects on colorectal cell proliferation, angiogenesis was assessed with a chorioallantoic membrane model and apoptosis was determined with annexin V staining. We found that DuP-697 alone exerted antiproliferative, antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. For the antiproliferative effect the half maximum inhibition concentration ($IC_{50}$) was $4.28{\times}10^{-8}mol/L$. Antiangiogenic scores were 1.2, 0.8 and 0.5 for 100, 10 and 1 nmol/L DuP-697 concentrations, respectively. We detected apoptosis in 52% of HT29 colorectal cancer cells after administration of 100 nmol/L DuP-697. Also in combination with the thyrosine kinase inhibitor E7080 strong antiproliferative, antiangiogenic and apoptotic effects on HT29 colorectal cancer cells were observed. This study indicates that DuP-697 may be a promising agent in the treatment of colorectal cancer. Additionally the increased effects observed in the combination with thyrosine kinase inhibitor give the possibility to use lower doses of DuP-697 and E7080 which can avoid and/or minimize side effects.


Colon cancer;DuP-697;COX-2 inhibition;tyrosine kinase inhibitor


  1. Mann M, Sheng H, Shao J, et al (2001). Targeting cyclooxygenase-2 and HER-2/neu pathway inhibits colorectal pathway inhibits colorectal carcinoma growth. Gastroenterology, 120, 1713-9.
  2. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006). VEGF receptor signaling - in control of vascular function. Nat Rev Mol Cell Biol, 7, 359-71.
  3. Pandurangan AK, Esa NM (2013). Dietary non-nutritive factors in targeting of regulatory molecules in colorectal cancer: an update. Asian Pac J Cancer Prev, 14, 5543-52.
  4. Jiang WQ, Fu FF, Li YX, et al (2012). Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice. J Zhejiang Univ Sci, 13, 663-75.
  5. Koki AT, Masferrer JL (2002). Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control, 9, 28-35.
  6. Ma JX, Sun YL, Wang YQ, et al (2013). Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF. Oncol Res, 20, 359-68.
  7. Masferrer JL, Leahy KM, Koki AT, et al (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-11.
  8. Masunaga R, Kohno H, Dhar DK, et al (2000). Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res, 6, 4064-8.
  9. Matsui J, Funahashi Y, Uenaka T, et al (2008). Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R)2 and VEGF-R3 kinase. Clin Cancer Res, 14, 5459-65.
  10. Matsui J, Yamamoto Y, Funahashi Y, et al (2008). E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small lung cancer H146, based on angiogenesis inhibition. Int J Cancer, 122, 664-71.
  11. Ogino H, Hanibuchi M, Kakiuchi S, et al (2011). E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. Mol Cancer Ther, 10, 1218-28.
  12. Glen H, Mason S, Patel H, Macleod K, Brunton VG (2011). E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer, 11, 309.
  13. Engelman JA, Settleman J (2008). Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev, 18, 73-9.
  14. Feng LL, Liu BX, Zhong JY, Sun LB, Yu HS (2014). Effect of grape procyanidins on tumor angiogenesis in liver cancer xenograft models. Asian Pac J Cancer Prev, 15, 737-41.
  15. Filardo EJ (2002). Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol, 80, 231-8.
  16. Gotink KJ, Verheul HM (2010). Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis, 13, 1-14.
  17. Grosch S, Maier TJ, Schiffmann S, Geisslinger G (2006). Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, 98, 736-47.
  18. Heuckmann JM, Rauh D, Thomas RK (2012). Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. J Clin Oncol, 30, 3417-20.
  19. Huang Wk, Chiou MJ, Yu KH, et al (2013). The association between low dose aspirin use and incidence of colorectal cancer: a nationwide cohort study. Aliment Pharmacol Ther, 38, 432-9.
  20. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al (2005). Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol, 23, 3502-8.
  21. Dannhardt G, Kiefer W (2001). Cyclooxygenase inhibitors-current status and future prospects. Eur J Med Chem, 36, 109-26.
  22. Churchman A, Baydoun AR, Hoffman R (2007). Inhibition of angiogenic tubule formation and induction of apoptosis in human endothelial cells by the selective cyclooxygenase-2 inhibitor 5-bromo-2-(4-fluorophenyl)-3-(methylsulfonyl) thiophene (DuP-697). Eur J Pharmacol, 573, 176-83.
  23. Coghill AE, Phipps AL, Bavry AA, et al (2012). The association between NSAİD use and colorectal cancer mortality: results from women's health initiative. Cancer Epidemial Biomarkers Prev, 21, 1966-73.
  24. Cohen SJ, Cohen RB, Meropol NJ (2005). Targeting signal transduction pathways in colorectal cancer more than skin deep. J Clin Oncol, 23, 5374-85.
  25. Darakhshan S, Bidmeshkipour A, Khazaei M, Rabzia A, Ghanbari A (2013). Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev, 14, 6869-74.
  26. Demirci B, Dadandi MY, Paper DH, Franz G, Başer KH (2003). Chemical composition of the essential oil of Phlomis linearis Boiss and Bal, and biological effects on CAM assay: a safety evaluation. Z Naturforsch C, 58, 826-9.
  27. Deng Y, Su Q, Mo J, et al (2013). Celecoxib downregulates CD133 expression through inhibition of the Wnt signaling pathway in colon cancer cells. Cancer Invest, 31, 97-102.
  28. Dubbelman AC, Rosing H, Thijssenb B, et al (2012). Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices. J Chromatography B Analyt Technol Biomed Life Sci, 8, 25-34.
  29. Ellis LM, Hicklin DJ (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer, 8, 579-91.
  30. Best L, Simmonds P, Baughan C, et al (2000). Palliative chemotherapy for advanced or metastatic colorectal cancer. Cochrane Database Syst Rev, 2, 1545.
  31. Toomey DP, Murphy JF, Conlon KC (2009). Cox-2, VEGF and tumour angiogenesis. Surgeon, 7, 174-80.
  32. Tortora G, Caputo R, Damiano V, et al (2003). Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res, 9, 1566-72.
  33. Altun A, Temiz TK, Balcı E, Polat ZA, Turan M (2013). Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination. Chin J Cancer Res, 25, 572-84.
  34. Blume-Jensen P, Hunter T (2001). Oncogenic kinase signalling. Nature, 411, 355-65.
  35. Bokemeyer C, Bondarenko I, Makhson A, et al (2009). Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 27, 663-71.
  36. Bruheim S, Kristian A, Uenaka T, et al (2011). Antitumuor activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. Int J Cancer, 129, 742-50.
  37. Burgermeister J, Paper DH, Vogl H, Linhardt RJ, Franz G (2002). LAPSvS1, a (1- ->3) - betagalactan sulfate and its effect on angiogenesis in vitro and in vivo. Carbohydr Res, 337, 1459-66.
  38. Choi S, Lim TG, Hwang MK, et al (2013). Rutin inhibits B[a] PDE-induced cyclooxygenase-2 expression by targeting EGFR kinase activity. Biochem Pharmacol, 86, 1468-75.
  39. Sartore-Biachi A, Martini M, Molinari F, et al (2009). PIK3CA mutations in colorectal cancer is associated with clinical resistance to EGRF- targeted monoclonal antibodies. Cancer Res, 69, 1851-7.
  40. Roche Diagnostics GmbH (2008). Introduction of the RTCA SP Instrument. RTCA SP Instrument Operator's Manuel, A. Acea Biosciences, Inc. 14-16.
  41. Ruder EH, Laiyemo AO, Graubard BI, et al (2011). Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol, 106, 1340-50.
  42. Saltz LB (2010). Adjuvant therapy for colon cancer. Surg Oncol Clin N Am, 19, 819-27.
  43. Schonthal AH (2006). Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus, 20, 21.
  44. Segal NH, Saltz LB (2009). Evolving treatment of advanced colon cancer. Annu Rev Med, 60, 207-19.
  45. Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-36.
  46. Stocmann C, Doedans A, Weidemann A, et al (2008). Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature, 456, 814-8.
  47. Tanwar L, Piplani H, Sanyal S (2010). Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor on 1,2-dimethylhydrazine dihydrochloride-inducede colon carcinogenesis. Asian Pac J Cancer Prev, 11, 1329-33.
  48. Thun MJ, Henley SJ, Patrono C (2002). Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst, 94, 252-66.
  49. Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, Gary BD, Keeton AB, Xi Y, Abadi AH, Grizzle WE, Piazza GA (2012). A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and ${\beta}$-catenin transcriptional activity. Cancer Prev Res, 5, 822-33.
  50. Van Loon K, Venook AP (2011). Adjuvant treatment of colon cancer: what is next? Curr Opin Oncol, 23, 403-9.
  51. Vanneman M, Dranoff G (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer, 12, 237-51.
  52. Wang D, Dubois RN (2010). The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene, 29, 781-8.
  53. Wolpin BM, Mater RJ (2008). Systemic treatment of colorectal cancer. Gastroenterology, 134, 1296-310.
  54. Xu K, Chang CM, Gao H, Shu HK(2009). Epidermal growth factor-dependent cyclooxygenase-2 induction in gliomas requires protein kinase C-delta. Oncogene, 28, 1410-20.
  55. Zhou LH, Hu Q, Sui H, Ci SJ, Wang Y, Liu NN, Yin PH, Qin JM, Li Q (2012). Tanshinone 11-a inhibits angiogenesis through down regulation of COX-2 in human colorectal cancer. Asian Pac J Cancer Prev, 13, 4453-8.
  56. Peng HL, Zhang GS, Liu JH, Gong FJ, Li RJ (2008). Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Ann Hematol, 87, 121-9.
  57. Pereg D, Lishner M (2005). Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Int Med, 258, 115-23.
  58. Piazza GA, Keeton AB, Tinsley HN, et al (2009). A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res, 2, 572-80.
  59. Tuccillo C, Romano M, Troiani T, et al (2005). Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res, 11, 1268-76.
  60. Turini ME, DuBois RN (2002). Cyclooxygenase-2: a therapeutic target. Annu Rev Med, 53, 35-57.

Cited by

  1. Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer vol.2015, pp.1537-744X, 2015,
  2. Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells vol.17, pp.3, 2016,
  3. PVT1 (rs13281615) and miR-146a (rs2910164) polymorphisms affect the prognosis of colon cancer by regulating COX2 expression and cell apoptosis pp.00219541, 2019,